Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Postmarketing Observational Study of Tolterodine Treatment on Overactive Bladder in Real Life Setting

NCT01488578 is registered in ClinicalTrials.gov with Pfizer's Upjohn has merged with Mylan to form Viatris Inc. as lead sponsor.

NCT NCT01488578
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01488578 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Postmarketing Observational Study of Tolterodine Treatment on Overactive Bladder in Real Life Setting
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase
Observational
Overall status
Completed
Start date
December 31, 2006
Completion date
March 31, 2011
Enrollment
11,157 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder